TREATMENT OF SIDE EFFECTS CAUSED BY ATYPICAL ANTIPSCHOTICS Russian patent published in 2023 - IPC A61K33/242 A61K47/54 A61K47/62 A61P3/04 A61P3/10 

FIELD: medicine.

SUBSTANCE: invention relates to the use of gold clusters associated with ligands for the treatment of side effects caused by an atypical antipsychotic in a subject. The use of a ligand-linked gold cluster is provided for the treatment of side effects caused by an atypical antipsychotic in a subject, wherein the ligand-linked gold cluster comprises the following: a gold core that has a diameter of less than 3 nm; and a ligand associated with the gold core, wherein the ligand is selected from the group consisting of L-cysteine and its derivatives, D-cysteine and its derivatives, cysteine-containing oligopeptides and derivatives thereof, and other thiol-containing compounds. L-cysteine and its derivatives are selected from the group consisting of L-cysteine, N-isobutyryl-L-cysteine (L-NIBC) and N-acetyl-L-cysteine (L-NAC); D-cysteine and its derivatives are selected from the group consisting of D-cysteine, N-isobutyryl-D-cysteine (D-NIBC) and N-acetyl-D-cysteine (D-NAC); cysteine-containing oligopeptides and their derivatives are cysteine-containing dipeptides, cysteine-containing tripeptides or cysteine-containing tetrapeptides; and other thiol-containing compounds are selected from the group consisting of 1-[(2S)-2-methyl-3-thiol-1-oxopropyl]-L(D)-proline, thioglycolic acid, mercaptoethanol, thiophenol, D-3-trolovol, N-(2-mercaptopropionyl)-glycine, dodecylmercaptan, 2-aminoethanethiol (CSH), 3-mercaptopropionic acid (MPA) and 4-mercaptobenic acid (p-MBA).

EFFECT: use of the invention makes it possible to significantly reduce the side effects caused by atypical antipsychotics.

7 cl, 13 dwg, 3 tbl, 3 ex